3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
10
Endocrine
2
NET
1
Genitourinary
1
Conditions
Neuroendocrine Tumors
1
Neoplasms
1
Interventions
lutetium Lu 177 dotatate
41
Everolimus
38
Magnetic Resonance Spectroscopy
18
Temozolomide
17
lanreotide
16
gallium Ga 68 dotatate
15
Octreotide
14
pembrolizumab
13
Nivolumab
13
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
surufatinib
9
pasireotide
9
Sunitinib
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Lutetium-177
8
Carboplatin
8
amino-acid, glucose, and electrolyte solution
6
Ipilimumab
6
Ga(III)-DOTATOC
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
copper dotatate CU-64
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
AMG 757
×
NET
×
Clear all
NCT06502977
2026-04-15
DeLLphi-307
Amgen
Phase 2
Active not recruiting
32 enrolled
9 charts